Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 51OTHER 36NIH 4NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Lung Neoplasms 1

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Has results × avelumab × Clear all
NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

SWOG Cancer Research Network

Phase 2 Terminated
6 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms

NCT04173507 2024-09-03

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡